Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients

被引:19
|
作者
Lawicki, S. [1 ]
Bedkowska, G. E. [1 ]
Wojtukiewicz, M. [2 ]
Szmitkowski, M. [1 ]
机构
[1] Med Univ Bialystok, Dept Biochem Diagnost, PL-15269 Bialystok, Poland
[2] Med Univ Bialystok, Dept Oncol, PL-15269 Bialystok, Poland
来源
ADVANCES IN MEDICAL SCIENCES | 2013年 / 58卷 / 02期
关键词
breast cancer; CA; 15-3; HGFs; tumor markers; COLONY-STIMULATING FACTOR; FACTOR M-CSF; STEM-CELL FACTOR; SERUM-LEVELS; CIRCULATING LEVELS; COLORECTAL-CANCER; OVARIAN-CANCER; FACTOR-I; ENDOMETRIAL; CARCINOMAS;
D O I
10.2478/ams-2013-0023
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: Plasma levels of selected hematopoietic cytokines: interleukin 3 (IL-3), stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF), and the tumor marker carcinoma antigen 15-3 (CA 15-3) in breast cancer (BC) patients were investigated and compared to control groups: benign breast tumor patients and healthy subjects. Material/Methods: Cytokine levels were determined by ELISA, CA 15-3-using the CMIA method. Results: A significant differences in the concentration of cytokines (with the exception of IL-3) and CA15-3 between the groups of BC patients, benign breast tumor patients and the healthy controls have been demonstrated. M-CSF has demonstrated higher or equal to CA 15-3 values of diagnostic sensitivity, specificity and the predictive values of positive and negative test results. The M-CSF area under the ROC curve (AUC) was the largest from all the cytokines tested and marginally lower than the AUC of CA 15-3. Conclusion: These findings suggest the usefulness of M-CSF in diagnosing breast cancer, especially when discriminating between cancer and non-carcinoma lesions.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 50 条
  • [41] Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer
    Molina, R
    Filella, X
    Zanon, G
    Pahisa, J
    Alicarte, J
    Munoz, M
    Farrus, B
    Ballesta, AM
    ANTICANCER RESEARCH, 2003, 23 (2A) : 1043 - 1050
  • [42] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients
    Lawicki, Slawomir
    Szmitkowski, Maciej
    Wojtukiewicz, Marek
    CLINICA CHIMICA ACTA, 2006, 371 (1-2) : 112 - 116
  • [43] Cancer panel analysis of circulating tumor cells in patients with breast cancer
    Lee, Cham Han
    Lee, Soo Jeong
    Choi, Sung Ho
    Ahn, Sei Hyun
    Son, Byung Ho
    Lee, Jong Won
    Yu, Jong Han
    Kwon, Nak-Jung
    Lee, Woo Chung
    Yang, Kap-Seok
    Lee, Dong Hyoung
    Han, Du Yeol
    Choi, Mi So
    Park, Pyeong-Soo
    Lee, Hyun Kyung
    Kim, Myoung Shin
    Lee, Jinseon
    Jeon, Byung Hee
    ONCOLOGY LETTERS, 2018, 16 (01) : 612 - 618
  • [44] Circulating cytokines as predictors of depression in patients with breast cancer
    Ho, Hsing-Ying
    Chen, Vincent Chin-Hung
    Tzang, Bor-Show
    Hsieh, Ching-Chuan
    Wang, Wen-Ke
    Weng, Yi-Ping
    Hsu, Ya-Ting
    Hsaio, Han-Pin
    Weng, Jun-Cheng
    Chen, Yi-Lung
    JOURNAL OF PSYCHIATRIC RESEARCH, 2021, 136 : 306 - 311
  • [45] Osteoblasts Are a Major Source of inflammatory Cytokines in the Tumor Microenvironment of Bone Metastatic Breast Cancer
    Bussard, Karen M.
    Venzon, David J.
    Mastro, Andrea M.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 111 (05) : 1138 - 1148
  • [46] PROSPECTIVE ASSESSMENT OF THE ROLE OF 5 TUMOR-MARKERS IN BREAST-CANCER
    ROBERTSON, JFR
    PEARSON, D
    PRICE, MR
    SELBY, C
    PEARSON, J
    BLAMEY, RW
    HOWELL, A
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (06) : 403 - 410
  • [47] Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
    Yerushalmi, R.
    Tyldesley, S.
    Kennecke, H.
    Speers, C.
    Woods, R.
    Knight, B.
    Gelmon, K. A.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 338 - 345
  • [48] The association of five preoperative serum tumor markers and pathological features in patients with breast cancer
    Lian, Mingjian
    Zhang, Cuixia
    Zhang, Dongdong
    Chen, Ping
    Yang, Huijing
    Yang, Yuanyuan
    Chen, Shidong
    Hong, Guolin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (05)
  • [49] EVALUATION OF SERUM TUMOR-MARKERS IN PATIENTS WITH ADVANCED OR RECURRENT BREAST-CANCER
    IWASE, H
    KOBAYASHI, S
    ITOH, Y
    FUKUOKA, H
    KUZUSHIMA, T
    IWATA, H
    YAMASHITA, T
    NAITOH, A
    ITOH, K
    MASAOKA, A
    BREAST CANCER RESEARCH AND TREATMENT, 1995, 33 (01) : 83 - 88
  • [50] Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value
    Molina, Rafael
    Auge, Jose M.
    Escudero, Jose M.
    Filella, Xavier
    Zanon, Gabriel
    Pahisa, Jaume
    Farrus, Blanca
    Munoz, Montserrat
    Velasco, Martin
    TUMOR BIOLOGY, 2010, 31 (03) : 171 - 180